)

Geron (GERN) investor relations material
Geron Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Executive summary
Achieved $49M in RYTELO net product revenue in Q2 2025, up 24% from Q1, with demand rising 17% and over 1,000 ordering accounts, up by 400 year-to-date.
Expanded commercial and medical affairs teams by over 20%, with new hires trained and deployed to drive further growth.
Appointed Harout Semerjian as President and CEO, bringing over 30 years of hematology and oncology experience.
Preparations underway for RYTELO launch in select EU countries in 2026 via third-party partners, following recent approval.
Over 95% enrollment reached in the Phase 3 ImpactMF trial for relapsed/refractory myelofibrosis, with full enrollment expected by year-end 2025.
Financial highlights
Q2 2025 net product revenue was $49M, up from $780K–$882K in Q2 2024, reflecting the first full quarters post-FDA approval.
Net loss for Q2 2025 was $16.4M ($0.02/share), a significant improvement from $67.4M ($0.10/share) in Q2 2024.
Operating expenses for Q2 2025 were $61.5M, down from $70.2M in Q2 2024; R&D expenses decreased 29% and SG&A down 2%.
Cash, cash equivalents, and marketable securities totaled $432.6M as of June 30, 2025, down from $502.9M at year-end 2024.
Six-month net product revenue reached $88.4M; six-month net loss was $36.2M versus $122.8M in the prior year period.
Outlook and guidance
FY 2025 operating expenses expected to be $270M–$285M, reflecting investments in commercialization, supply, and EU launch preparations.
Expanded commercial and medical teams expected to impact performance by year-end 2025.
Existing cash and anticipated RYTELO revenues expected to fund operations for the foreseeable future, with access to additional debt funding if needed.
European launch targeted for select markets in 2026, pending favorable reimbursement.
Company expects to reach profitability without additional financing if current sales and expense targets are met.
Next Geron earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage